
Streaming: 'House Of The Dragon' Welcomes 3 Fresh Knights; 'Rick And Morty' Season 8 Gets Release Date
New seasons galore, folks! That's right, the follow-up to two intensely-beloved series is just around the corner, and we're providing you with the latest tea on what's what.
From new cast members joining the fray, to a full-blown trailer and release date, here's what to expect from two huge streaming shows this side of the solar system.
Tom Cullen, Joplin Sibtain & Barry Sloane Knighted In 'House Of The Dragon'
With every new season of a slowly-expanding series, it's often natural that we get to see new faces that will help contribute to and expand the plot; the same is true for the hit series 'House of the Dragon'.
As the third season of the show slowly approaches, we are slowly being drip-fed information, the biggest and most recent of which is that three new knights are joining Westeros' ranks.
Introducing Ser Adrian Redfort, Ser Luthor Largent, and Ser Jon Roxton, who will be played by Barry Sloane ('Passenger,' 'Six'), Tom Cullen ('Weekend,' 'Knighfall'), and Joplin Sibtain ('Star Wars: Andor,' 'Ghost Recon: Alpha'), respectively.
We can make the argument that these actors are here to portray your regular rank-and-file soldiers, but those who are familiar with George R. R. Martin's work 'Fire & Blood' know that these characters' names are no slouch.
Starting off with Ser Adrian Redfort. Besides being a part of House Redfort, he is also a member of Rhaenyra Targaryen's Queensguard following the seizing of King's Landing, where he was quickly recruited to serve alongside Lord Commander Lorent Marbrand.
Next up is Ser Luthor Largent, an equally powerful and imposing warrior. He is a common man with no noble lineage, who rose to the rank of knight. He's known for his exceptional track record through the ranks as an officer and later, as commander of the City Watch of King's Landing. He is a towering figure, almost reaching seven feet tall (~213 cm tall), and is so strong that it is rumoured that he was able to kill a warhorse with one punch.
And lastly is Ser Jon Roxton: an honoured knight and head of House Roxton who allied his forces with Aegon II Targaryen and the Greens during the civil war, the Dance of Dragons. He is headstrong and quick to anger, but he has the skill to back it up. Pair this up with his famous blade, the Orphan-Maker, and he's a force to be reckoned with.
Aside from these three, we'll also be seeing newer faces such as James Norton as Ormund Hightower, Tommy Flanagan as Lord Roderick Dustin, and Dan Fogler as Ser Torrhen Manderly. Naturally, sharing the screen with them are previous 'House of the Dragon' actors such as Matt Smith, Olivia Cooke, Steve Toussaint, Rhys Ifans, Fabien Frankel, Ewan Mitchell, Sonoya Mizuno, Harry Collett, Bethany Antonia, Phoebe Campbell, Phia Saban, Jefferson Hall, Matthew Needham, Tom Bennett, Kieran Bew, Kurt Egyiawan, Freddie Fox, Clinton Liberty, Gayle Rankin, and Abubakar Salim.
Filming for the upcoming season has already begun and is projected to be released in summer 2026.
'Rick and Morty' Season 8 Drops Globally On 26th May On HBO Max
After almost two years of waiting, the newest season of the beloved sci-fi comedy is almost upon us! Not only did the folks over at Adult Swim provide us with a brief trailer of what to expect, the team was also courteous enough to share the release date for the highly-anticipated continuation of the beloved series — 26th May.
A brief synopsis reads, 'Rick and Morty is back for Season Eight! Life has meaning again! Anything is possible! Look out for adventures with Summer, Jerry, Beth, and the other Beth. Maybe Butter Bot will get a new task? Whatever happens, you can't keep Rick and Morty down for long. People have tried!' Naturally, this doesn't really discuss what to expect from the upcoming season, but it is something we expected from the series.
We can see the family once again travelling across the stars, fighting and often escaping alien forces, and even the church? We also get to see more of Space Beth, who we all know took a back seat in season 7, though she's a bit worse for wear. However, that isn't stopping her from squaring up against the Galactic Federation. We also noticed Earth Beth and Summer having a fight over their new hairstyles, Jerry trapped in a crystal, and, of course, alternate Ricks.
Being an episodic series, it's often hard to pinpoint the theme of the whole season in a single viewing, doubly so if you're only analysing the trailer. However, following season 7's theme of healing and reconnecting, we might see the series continue on this path, especially with the death of Rick Prime and the seemingly peaceful resolution with Evil Morty (who just wants to be alone). Naturally, this is all conjecture, and it is too early to tell.
What we know for sure is that the series will now be moving away from Netflix. As you may have known, the series has been removed from the streaming giant due to licensing issues, as Netflix failed to renew the series. It has since been with HBO Max, where it can be streamed for the foreseeable future. It can also be streamed on Hulu.
Dan Harmon and Scott Marder, who also acts as showrunner, are executive producers of 'Rick and Morty' season 8, which will star Ian Cardoni, Harry Belden, Sarah Chalke, Chris Parnell, and Spencer Grammer.
Sources: Entertainment Weekly, Blunt
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
![2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview](/_next/image?url=https%3A%2F%2Fwww.gannett-cdn.com%2Fauthoring%2Fimages%2FDataSkriveSportsbookWire%2F2025%2F04%2F16%2FSSBK%2F83116869007-14991234.jpeg%3Fauto%3Dwebp%26crop%3D1199%2C676%2Cx0%2Cy73%26format%3Dpjpg%26width%3D1200&w=3840&q=100)
![2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fusatoday.com.png&w=48&q=75)
USA Today
25 minutes ago
- USA Today
2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview
2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview Carson Branstine (No. 231 ranking) will take on Elena-Gabriela Ruse (No. 80) in the Round of 16 of the Libema Open on Thursday, June 12. Ruse is the favorite against Branstine for this match, with -275 odds against the the underdog's +270. Tennis odds courtesy of BetMGM Sportsbook. Odds updated Wednesday at 6:35 PM ET. For a full list of sports betting odds, access USA TODAY Sports Betting Scores Odds Hub. Carson Branstine vs. Elena-Gabriela Ruse matchup info Tournament: Libema Open Libema Open Round: Round of 16 Round of 16 Date: Thursday, June 12 Thursday, June 12 Court Surface: Grass Watch the Tennis Channel and more sports on Fubo! Branstine vs. Ruse Prediction Based on the implied probility from the moneyline, Branstine has a 73.3% to win. Branstine vs. Ruse Betting Odds Branstine vs. Ruse matchup performance & stats


CNBC
25 minutes ago
- CNBC
Elon Musk's favorability among Republicans dropped 16 points since March, Quinnipiac says
Elon Musk's official role in the Trump administration recently came to an end. Many Republicans won't be sad to see less of him, according to the results of Quinnipiac University's latest public opinion survey. While a majority of Republicans still hold a favorable view of Musk, the number fell to 62% in the poll out Wednesday, down from 78% in March, Quinnipiac said. Overall, the Quinnipiac poll found that 30% of self-identified voters surveyed in the U.S. hold a favorable opinion of Musk, according to polling from June 5 to June 9. Republican and Democratic voters remain deeply divided in their views of the world's richest man, who contributed nearly $300 million to propel President Donald Trump back to the White House. Only 3% of Democrats surveyed said they held a favorable of view of the Tesla CEO, who was once seen as an environmental leader appealing to liberal values. Musk didn't respond to a request for comment. Musk and Trump had a very public falling out last week that started with Musk's disapproval of the president's spending bill and escalated into an all-out war of words that played out on social media. Musk said on Wednesday that he regretted some of the posts he made about Trump last week, adding that "they went too far." Even with a slide in his favorability, Musk is still popular among Republicans after his time running the Department of Government Efficiency (DOGE), an effort to dramatically slash the size of the federal government. Among the Republican respondents to the early June poll, 80% rated Musk and DOGE's work as either excellent or good, while 13% said it was either not so good or poor. In the March poll, 82% of Republicans surveyed said they thought Musk and DOGE were helping the country. Read the full survey results here.
Yahoo
25 minutes ago
- Yahoo
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data